News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ChemBridge Research Laboratories, Inc. And St. Jude Children's Research Hospital, Inc. Renew Collaborative Cancer Therapy Discovery Agreement


10/19/2005 5:12:53 PM

SAN DIEGO, May 4 /PRNewswire/ -- ChemBridge Research Laboratories, Inc. (CRL) today announced extension of a previously unannounced multi-year agreement with St. Jude Children's Research Hospital, Inc. (St. Jude) which will apply CRL's discovery medicinal chemistry platform to targets related to certain St. Jude cancer therapy research projects. Under the terms of the agreement, CRL and St. Jude researchers will work on hit to lead and lead development against targets that are related to anaplastic lymphoma kinase (ALK), such as the insulin-like growth factor receptor (IGF1R). ALK was discovered in the laboratory of Stephan W. Morris, M.D., who will lead the scientific team at St. Jude. CRL had previously provided Kinase Targeted Libraries to St. Jude that were specifically designed to interact with the binding-site recognition features of this target family. This library was screened in the Morris laboratory and a number of hits were discovered that showed selective inhibition of ALK when compared to a small panel of kinases, including the highly homologous insulin receptor kinase.

"Our interactions with CRL and its scientists have already been quite fruitful, and we now look forward to extending our work with them as we seek to further optimize and develop selective kinase inhibitors. I would highly recommend CRL to other academically-based investigators as an outstanding partner for their drug discovery projects," said Steve Morris MD, Full Member St. Jude and co-chair of the Joint Research Management Committee (JRMC).

"We are pleased to extend our collaboration with Dr. Stephan Morris and colleagues. This collaboration complements our well established strengths in discovery libraries and medicinal chemistry as well as our growing internal capabilities in assay development, molecular biology and protein expression," stated Thomas R. Webb Ph.D., Vice President of Research and Development at ChemBridge and CRL and co-chair JRMC. "We are impressed by the excellent progress made by the talented scientists from this discovery team in this unique research niche and we are looking forward to continued contributions in the discovery of novel selective kinase inhibitor leads for cancer therapy, This collaboration has been fruitful due to the mutually productive interactions, the rapid turn-around of biological data from St. Jude and our hit-follow-up and lead optimization chemistry efforts," said Rongshi Li Director of High Throughput Medicinal Chemistry at CRL and a member of the St. Jude/CRL JRMC.

ChemBridge Research Laboratories, Inc. (CRL), http://www.chembridgeresearch.com/, is a privately held chemistry-based small molecule drug discovery company. It was founded in 2000 as a spin-off of ChemBridge Corporation. CRL is located in San Diego, in custom built, state-of-the-art research facilities, with 58 employees including 48 scientists (31 Ph.D.) and is led by a research management team with substantial experience in the pharmaceutical and biotech industry. CRL is focused on collaborative medicinal chemistry support,

hit-to-lead and lead optimization programs, and has a track record of consistently exceeding the goals on all of its research collaborations including major multi-year alliances with Pfizer, Inc. and Merck & Co. CRL's internal drug discovery efforts leverage the company's comprehensive medicinal chemistry platform and its core expertise in kinase and GPCR areas. CRL's internal projects include one obesity and two oncology programs.

ChemBridge Corporation, http://www.chembridge.com/, is a privately-held leading global discovery chemistry CRO. Founded in Chicago in 1993 ChemBridge has funded its growth by product sales and services and has developed into a global company with 350 employees. ChemBridge has an impeccable track record of quality and deliverability. As a substantial international company ChemBridge operates a large, state-of-the-art offshore discovery chemistry research site in Moscow, Russia and has its corporate headquarters in San Diego, European offices in the UK, with a marketing agency in Japan. Over 400 pharmaceutical and biotech companies and universities worldwide have taken advantage of ChemBridge's portfolio of advanced discovery chemistry services and products including its library of 600,000 diverse drug-like small molecule compounds.

St. Jude Children's Research Hospital, http://www.stjude.org/. Clinical Research Environment: St. Jude Children's Research Hospital, the only NCI funded cancer center devoted solely to children, specializes in the development of new protocols for the treatment of cancer and other catastrophic diseases of childhood. The institution's 92 faculty-level clinical investigators and 38 clinical fellows collaborate extensively with basic science investigators. St. Jude provides clinical care to thousands of patients each year (approximately 500 new patients yearly), irrespective of ability to pay. Essentially all patients are treated on active clinical research protocols, many of which incorporate translational research findings. All staff are experienced in the conduct of clinical trials.

Basic Science Research Environment: St. Jude Children's Research Hospital is a premier research center that has 83 faculty-level basic science investigators and 191 postdoctoral research associates. Faculty have appointments at the University of Tennessee, Memphis, Colleges of Medicine and Pharmacy, and they direct students in those and other graduate programs. Research is conducted in the 240,000-sq.-ft., 5-story Danny Thomas Research Center, which is designed to provide an optimal environment for research in the basic sciences. A new Integrated Research Center has recently added more than 80,000 square feet of laboratory space. It also allots 165,000 square feet to animal resources, allowing the expanded use of transgenic and knockout mice. An additional advantage for investigators is the Hartwell Center for Bioinformatics and Biotechnology, which offers extensive, state-of-the-art biotechnology and bioinformatics support. St. Jude offers a rich intellectual environment in which basic scientists and clinical investigators collaborate in translational research.

ChemBridge Research Laboratories, Inc.

CONTACT: Thomas R. Webb, Ph.D., Vice President of Research & Developmentof ChemBridge Corporation and ChemBridge Research Laboratories, Inc.,+1-858-451-7400


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES